EP3328364A4 - Neuartige duale orale zusammensetzung aus dexlansoprazol mit verzögerter freisetzung - Google Patents

Neuartige duale orale zusammensetzung aus dexlansoprazol mit verzögerter freisetzung Download PDF

Info

Publication number
EP3328364A4
EP3328364A4 EP16829940.2A EP16829940A EP3328364A4 EP 3328364 A4 EP3328364 A4 EP 3328364A4 EP 16829940 A EP16829940 A EP 16829940A EP 3328364 A4 EP3328364 A4 EP 3328364A4
Authority
EP
European Patent Office
Prior art keywords
dexlansoprazole
delayed release
oral composition
release oral
novel dual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16829940.2A
Other languages
English (en)
French (fr)
Other versions
EP3328364A1 (de
Inventor
Anwar Siraj DAUD
Shamsuddin JAMALUDDIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZIM Laboratories Ltd
Original Assignee
ZIM Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57884420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3328364(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ZIM Laboratories Ltd filed Critical ZIM Laboratories Ltd
Publication of EP3328364A1 publication Critical patent/EP3328364A1/de
Publication of EP3328364A4 publication Critical patent/EP3328364A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP16829940.2A 2015-07-28 2016-07-27 Neuartige duale orale zusammensetzung aus dexlansoprazol mit verzögerter freisetzung Withdrawn EP3328364A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2851MU2015 2015-07-28
PCT/IB2016/054467 WO2017017615A1 (en) 2015-07-28 2016-07-27 Novel dual delayed release oral composition of dexlansoprazole

Publications (2)

Publication Number Publication Date
EP3328364A1 EP3328364A1 (de) 2018-06-06
EP3328364A4 true EP3328364A4 (de) 2019-01-02

Family

ID=57884420

Family Applications (1)

Application Number Title Priority Date Filing Date
EP16829940.2A Withdrawn EP3328364A4 (de) 2015-07-28 2016-07-27 Neuartige duale orale zusammensetzung aus dexlansoprazol mit verzögerter freisetzung

Country Status (6)

Country Link
EP (1) EP3328364A4 (de)
BR (1) BR112018001539A2 (de)
CL (1) CL2018000220A1 (de)
CO (1) CO2018002046A2 (de)
PE (1) PE20181012A1 (de)
WO (1) WO2017017615A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102727681B1 (ko) * 2019-02-08 2024-11-07 주식회사유한양행 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제
CN111991367A (zh) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 一种埃索美拉唑镁脉冲微丸胶囊剂及制备方法
KR102471545B1 (ko) * 2020-11-20 2022-11-29 서울대학교 산학협력단 덱스란소프라졸을 유효성분으로 포함하는 pH 의존성 타블렛-인-캡슐 복합제제 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (en) * 2011-12-21 2013-08-01 Hetero Research Foundation Controlled release solid oral compositions of dexlansoprazole

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
WO2013111149A1 (en) * 2011-12-21 2013-08-01 Hetero Research Foundation Controlled release solid oral compositions of dexlansoprazole

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017017615A1 *

Also Published As

Publication number Publication date
EP3328364A1 (de) 2018-06-06
PE20181012A1 (es) 2018-06-26
CL2018000220A1 (es) 2018-07-20
WO2017017615A1 (en) 2017-02-02
BR112018001539A2 (pt) 2018-09-18
CO2018002046A2 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
EP3171871A4 (de) Zusammensetzung mit fester dosierform für orale und sublinguale verabreichung von cannabinoiden
EP3096759A4 (de) Formulierungen aus pridopidin mit modifizierter freisetzung
EP3092256A4 (de) Verbindungen und zusammensetzungen für die immuntherapie
EP3139920A4 (de) Antivirale verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung davon
EP3242940A4 (de) Verfahren und zusammensetzungen für kombinationsimmuntherapie
EP3286213A4 (de) Verfahren und zusammensetzungen für eine kombinationsimmuntherapie
EP3102555A4 (de) Zusammensetzungen von verbindungen und verwendungen davon
EP3145893A4 (de) Kombinierte zementzusammensetzungen zur verzögerung des abbindens
EP3253403A4 (de) Verfahren und zusammensetzungen für verbesserte kognition
EP3302439A4 (de) Therapeutische zusammensetzung
EP3210613A4 (de) Zusammensetzung zur äusseren anwendung
EP3277755A4 (de) Algenmischzusammensetzungen ohne weichmacher
EP3248475A4 (de) Zusammensetzung
EP3323837A4 (de) Zusammensetzung
EP3148645A4 (de) Orale pharmazeutische zusammensetzung aus isotretinoin
EP3491153A4 (de) Zuckerzusammensetzung
EP3250562A4 (de) Kristalline formen von c21h22ci2n4o2
EP3138569A4 (de) Zusammensetzung zur äusseren anwendung
EP3214078A4 (de) 3-arylbenzofuranon-verbindung und daraus geformte zusammensetzung
EP3302467A4 (de) Kombinationszusammensetzungen zur immuntherapie
EP3202404A4 (de) Orale formulierung von a-nor-5alpha-androstan-verbindung
EP3302438A4 (de) Orale pharmazeutische zusammensetzung aus isotretinoin
EP3148644A4 (de) Orale pharmazeutische zusammensetzung aus isotretinoin
EP3174601A4 (de) Orale pharmazeutische zusammensetzung aus isotretinoin
EP3328364A4 (de) Neuartige duale orale zusammensetzung aus dexlansoprazol mit verzögerter freisetzung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20181203

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/48 20060101ALI20181127BHEP

Ipc: A61K 9/50 20060101AFI20181127BHEP

Ipc: A61K 9/62 20060101ALI20181127BHEP

Ipc: A61K 31/4439 20060101ALI20181127BHEP

Ipc: A61K 9/58 20060101ALI20181127BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20210202